<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844385</url>
  </required_header>
  <id_info>
    <org_study_id>GASTO-1071</org_study_id>
    <nct_id>NCT04844385</nct_id>
  </id_info>
  <brief_title>Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>A Prospective Single-arm Phase Ⅱ Study of Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II randomized study is to determine the efficacy and toxicity of toripalimab plus&#xD;
      neoadjuvant chemotherapy combined with chemoradiotherapy for locally advanced unresectable&#xD;
      esophageal squamous cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase II randomized study is to determine the efficacy and toxicity of toripalimab plus&#xD;
      neoadjuvant chemotherapy combined with chemoradiotherapy for locally advanced unresectable&#xD;
      esophageal squamous cell carcinoma.&#xD;
&#xD;
      All patients were planned to receive 2 cycle of toripalimab plus paclitaxel/nedaplatin as&#xD;
      neoadjuvant therapy. Then they all receive radical dose of chest radiation and concurrent&#xD;
      chemotherapy of capecitabine (PO 1000 mg/m2, bid, d1-d14, q3w).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year progression-free survival rate</measure>
    <time_frame>2-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year overall survival rate</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response rate</measure>
    <time_frame>2 months after radiotherapy</time_frame>
    <description>the percentage of patients who had partial remission or complete remission after therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of grade 3 or 4 toxicities according to CTCAE4.0</measure>
    <time_frame>1 year after therapy</time_frame>
    <description>the percentage of patients who develop grade 3 or 4 toxicities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year distant metastasis-free survival</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year locoregional recurrence-free survival</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by QLQ-C30</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Toripalimab plus Paclitaxel/Nedaplatin followed by concurrent chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in experimental group receive 2 cycles Toripalimab plus Paclitaxel/Nedaplatin, then followed by daily simultaneous modulated accelerated radiotherapy combined with Capecitabine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>Toripalimab 240 mg, d1, Q3w for two cycles</description>
    <arm_group_label>Toripalimab plus Paclitaxel/Nedaplatin followed by concurrent chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel-albumin</intervention_name>
    <description>Paclitaxel-albumin 260 mg/m2, d1, Q3w for two cycles</description>
    <arm_group_label>Toripalimab plus Paclitaxel/Nedaplatin followed by concurrent chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nedaplatin</intervention_name>
    <description>Nedaplatin 75mg/m2, d1, Q3w for two cycles</description>
    <arm_group_label>Toripalimab plus Paclitaxel/Nedaplatin followed by concurrent chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SMART</intervention_name>
    <description>Once-daily simultaneous modulated accelerated radiotherapy (PTV-GTV: 60Gy/24f )</description>
    <arm_group_label>Toripalimab plus Paclitaxel/Nedaplatin followed by concurrent chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000 mg/m2, bid, d1-14, q3w during radiotherapy</description>
    <arm_group_label>Toripalimab plus Paclitaxel/Nedaplatin followed by concurrent chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically confirmed esophageal squamous cell carcinoma&#xD;
&#xD;
          -  patients have measurable or evaluable lesions based on the Response Evaluation&#xD;
             Criteria in Solid Tumors (RECIST) criteria&#xD;
&#xD;
          -  unresectable T2-4 N0-3 M0 confirmed by CT or MRI&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  no previous chest radiotherapy, immunotherapy or biotherapy.&#xD;
&#xD;
          -  hemoglobin≥10 mg/dL, platelet≥100000/μL,absolute neutrophil count ≥1500/μL&#xD;
&#xD;
          -  serum creatinine ≤1.25 times the upper normal limit(UNL), or creatinine clearance≥60&#xD;
             ml/min&#xD;
&#xD;
          -  bilirubin ≤1.5 times UNL, AST（SGOT）≤2.5 times UNL ,ALT（SGPT）≤2.5 times UNL,alkaline&#xD;
             phosphatase ≤5 times UNL&#xD;
&#xD;
          -  FEV1 &gt;0.8 L&#xD;
&#xD;
          -  CB6 within normal limits&#xD;
&#xD;
          -  patients and their family signed the informed consents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous or recent another malignancy, except for nonmelanoma skin cancer or cervical&#xD;
             cancer in situ&#xD;
&#xD;
          -  contraindication for chemotherapy&#xD;
&#xD;
          -  women in pregnancy, lactation period, or no pregnancy test 14 days before the first&#xD;
             dose&#xD;
&#xD;
          -  women who has the probability of pregnancy without contraception&#xD;
&#xD;
          -  tendency of hemorrhage&#xD;
&#xD;
          -  in other clinical trials within 30 days&#xD;
&#xD;
          -  addicted in drugs or alcohol, AIDS patients&#xD;
&#xD;
          -  uncontrollable seizure or psychotic patients without self-control ability&#xD;
&#xD;
          -  severe allergy or idiosyncrasy&#xD;
&#xD;
          -  not suitable for this study judged by researchers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Liu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun yat-sen universtiy cancer center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Qiu, Professor</last_name>
    <phone>+86-020-87343031</phone>
    <email>qiubo@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Qiu, Professor</last_name>
      <phone>020-87343031</phone>
      <email>qiubo@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999 May 5;281(17):1623-7.</citation>
    <PMID>10235156</PMID>
  </reference>
  <reference>
    <citation>Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002 Mar 1;20(5):1167-74.</citation>
    <PMID>11870157</PMID>
  </reference>
  <reference>
    <citation>Chen Y, Ye J, Zhu Z, Zhao W, Zhou J, Wu C, Tang H, Fan M, Li L, Lin Q, Xia Y, Li Y, Li J, Jia H, Lu S, Zhang Z, Zhao K. Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial. J Clin Oncol. 2019 Jul 10;37(20):1695-1703. doi: 10.1200/JCO.18.02122. Epub 2019 Mar 28.</citation>
    <PMID>30920880</PMID>
  </reference>
  <reference>
    <citation>Gaspar LE, Winter K, Kocha WI, Coia LR, Herskovic A, Graham M. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. Cancer. 2000 Mar 1;88(5):988-95.</citation>
    <PMID>10699886</PMID>
  </reference>
  <reference>
    <citation>Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, Lee SH, Bennouna J, Kato K, Shen L, Enzinger P, Qin SK, Ferreira P, Chen J, Girotto G, de la Fouchardiere C, Senellart H, Al-Rajabi R, Lordick F, Wang R, Suryawanshi S, Bhagia P, Kang SP, Metges JP; KEYNOTE-181 Investigators. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol. 2020 Dec 10;38(35):4138-4148. doi: 10.1200/JCO.20.01888. Epub 2020 Oct 7.</citation>
    <PMID>33026938</PMID>
  </reference>
  <reference>
    <citation>Kato K, Shah MA, Enzinger P, Bennouna J, Shen L, Adenis A, Sun JM, Cho BC, Özgüroğlu M, Kojima T, Kostorov V, Hierro C, Zhu Y, McLean LA, Shah S, Doi T. KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol. 2019 Apr;15(10):1057-1066. doi: 10.2217/fon-2018-0609. Epub 2019 Feb 8.</citation>
    <PMID>30735435</PMID>
  </reference>
  <reference>
    <citation>Fan TY, Xing J, Lu J, Liu TH, Xu M, Zhang YJ, Shao Q, Li JB, Yu JM. Phase I/II study of induction chemotherapy plus concurrent chemotherapy and SMART-IMRT-based radiotherapy in locoregionally-advanced nasopharyngeal cancer. Oncol Lett. 2013 Mar;5(3):889-895. Epub 2013 Jan 15.</citation>
    <PMID>23426016</PMID>
  </reference>
  <reference>
    <citation>Koom WS, Kim TH, Shin KH, Pyo HR, Kim JY, Kim DY, Yoon M, Park SY, Lee DH, Ryu JS, Jung YS, Lee SH, Cho KH. SMART (simultaneous modulated accelerated radiotherapy) for locally advanced nasopharyngeal carcinomas. Head Neck. 2008 Feb;30(2):159-69.</citation>
    <PMID>17764088</PMID>
  </reference>
  <reference>
    <citation>Butler EB, Teh BS, Grant WH 3rd, Uhl BM, Kuppersmith RB, Chiu JK, Donovan DT, Woo SY. Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):21-32.</citation>
    <PMID>10477002</PMID>
  </reference>
  <reference>
    <citation>Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, Cox JD, Komaki R. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):468-74. doi: 10.1016/j.ijrobp.2010.10.023. Epub 2010 Dec 1.</citation>
    <PMID>21123005</PMID>
  </reference>
  <reference>
    <citation>Song YP, Ma JB, Hu LK, Zhou W, Chen EC, Zhang W. Phase I/II study of hypofractioned radiation with three-dimensional conformal radiotherapy for clinical T3-4N0-1M0 stage esophageal carcinoma. Technol Cancer Res Treat. 2011 Feb;10(1):25-30.</citation>
    <PMID>21214285</PMID>
  </reference>
  <reference>
    <citation>Ma JB, Wei L, Chen EC, Qin G, Song YP, Chen XM, Hao CG. Moderately hypofractionated conformal radiation treatment of thoracic esophageal carcinoma. Asian Pac J Cancer Prev. 2012;13(8):4163-7.</citation>
    <PMID>23098423</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hui Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Toripalimab, Neoadjuvant, Concurrent Chemoradiotherapy, Esophageal Squamous Cell Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Nedaplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

